Drug Trial Radar · NCT06546800
SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,100
Planned (sponsor's estimate)
Start
May 27, 2025
Primary completion
Oct 28, 2027
Study completion Oct 28, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 9, 2024
Design
- Study type
- Observational
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This post-marketing study is a multicenter cohort study in individuals aged 60 years or older vaccinated with Abrysvo (RSV vaccine)designed to confirm the safety in individuals aged 60 years or older under actual clinical practice in Japan.
Conditions
- Respiratory Syncytial Virus Infection
Interventions
RSVpreF vaccineBiological
Injection in the muscle, 1 dose 0.5mL
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of individuals aged 60 years or older reporting Adverse Reactions for 28 days after vaccination.Time frame: From the day of vaccination up to 28 days after vaccination.
- Percentage of individuals aged 60 years or older reporting Serious Adverse Reactions from the day of vaccination up to 28 days after vaccination.Time frame: From the day of vaccination up to 28 days after vaccination.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pfizer
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.